Dr. Joykumar G. Patel, M.D.
Hepatology (Hepatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 387
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
OK license 27793
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Integris Baptist Medical Center, Inc Oklahoma City, OK
- Integris Southwest Medical Center Oklahoma City, OK
- Ssm Health St Anthony Hospital - Shawnee Shawnee, OK
- Integris Health Edmond Hospital Edmond, OK
- Integris Canadian Valley Hospital Yukon, OK
Medical groups
- Zuhdi Transplant Physicians (49 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 387
- Services billed
- 700
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 320 | 254 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 122 | 41 |
| New patient office or other outpatient visit, 60-74 minutes | 50 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 36 | 34 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 152 payments worth $151,693 in total to this clinician.
| Madrigal Pharmaceuticals | $53,372 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $37,914 |
| Gilead Sciences, Inc. | $18,939 |
| Intercept Pharmaceuticals, Inc. | $17,063 |
| Novo Nordisk Inc | $14,414 |
| AbbVie Inc. | $9,893 |
| Mallinckrodt Hospital Products Inc. | $97.45 |
| Compensation for services other than consulting (speaking, faculty) | $119,026 |
|---|---|
| Travel and Lodging | $12,580 |
| Speaking at a medical education program | $10,340 |
| Food and Beverage | $5,347 |
| Consulting Fee | $4,400 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,891 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $7,350 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Ipsen Biopharmaceuticals, Inc Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,096 |
| Madrigal Pharmaceuticals Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $4,400 |
| Ipsen Biopharmaceuticals, Inc Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
All 67 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $2,340 |
| Madrigal Pharmaceuticals Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Novo Nordisk Inc Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $2,340 |
| AbbVie Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $2,375 |
| Ipsen Biopharmaceuticals, Inc Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Nov 4, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Norman, OK · in-kind | $50.40 |
| Madrigal Pharmaceuticals Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4261399;AHM;11402745 | $3,030 |
| Gilead Sciences, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4249394;GTF;11402745 | $600 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,891 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $724 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $374 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $221 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $2,375 |
| Madrigal Pharmaceuticals Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Aug 27, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Tulsa, OK · in-kind | $986 |
| Gilead Sciences, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) Vemlidy · HBV Company’s description;4179893;AHM;11402745 | $3,030 |
| AbbVie Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $3,800 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $449 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $309 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $55.00 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $346 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $310 |
| AbbVie Inc. Jul 11, 2025 | Travel and Lodging MAVYRET · VIROLOGY · travel to DENVER, CO · in-kind | $40.00 |
| Madrigal Pharmaceuticals Jul 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jul 8, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to STILLWATER, OK · in-kind | $480 |
| Ipsen Biopharmaceuticals, Inc Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,096 |
| Ipsen Biopharmaceuticals, Inc Jun 17, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Wichita, KS · in-kind | $1,092 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,230 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to SHERIDAN, WY · in-kind | $580 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to SHERIDAN, WY · in-kind | $208 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to SHERIDAN, WY | $203 |
| Intercept Pharmaceuticals, Inc. Jun 4, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $2,640 |
| Intercept Pharmaceuticals, Inc. Jun 4, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to St. Louis, MO | $15.00 |
| Intercept Pharmaceuticals, Inc. Jun 3, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,520 |
| Intercept Pharmaceuticals, Inc. Jun 3, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chesterfield, MO · in-kind | $619 |
| Intercept Pharmaceuticals, Inc. Jun 3, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chesterfield, MO | $118 |
| Ipsen Biopharmaceuticals, Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Intercept Pharmaceuticals, Inc. May 8, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $1,540 |
| Gilead Sciences, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4124260;AHM;11402745 | $3,030 |
| Madrigal Pharmaceuticals Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Apr 28, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to TULSA, OK · in-kind | $860 |
| Gilead Sciences, Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4116183;AHM;11402745 | $3,940 |
| Gilead Sciences, Inc. Apr 23, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Tulsa, OK · in-kind Company’s description;4328133;AHM;11402745 | $737 |
| Gilead Sciences, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4112160;AHM;11402745 | $3,030 |
| Intercept Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Oklahoma City, OK · in-kind | $190 |
| Intercept Pharmaceuticals, Inc. Apr 3, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $2,640 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $4,400 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $298 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $49.00 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $257 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $204 |
| Madrigal Pharmaceuticals Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,820 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026728;GTF;11402745 | $569 |
| Madrigal Pharmaceuticals Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Feb 25, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to TULSA, OK · in-kind | $1,010 |
| Ipsen Biopharmaceuticals, Inc Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $7,350 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $681 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $299 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.